Skip to main content

CareDx, Inc.

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

CDNA$80.77-4.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Revenue:
Testing services revenue$72,168$60,807$196,122$185,562
Product revenue12,47810,21235,12129,416
Patient and digital solutions revenue15,40911,86440,17632,228
Total revenue100,05582,883271,419247,206
Operating expenses:
Cost of testing services14,70513,44745,22441,387
Cost of product5,6296,21216,19617,854
Cost of patient and digital solutions10,3207,91326,30722,264
Research and development16,76917,48652,12355,890
Sales and marketing24,44919,80271,71960,634
General and administrative28,42931,74478,88192,791
Litigation settlement expense——5,710—
Total operating expenses100,30196,604296,160290,820
Loss from operations(246)(13,721)(24,741)(43,614)
Other income:
Interest income, net2,0133,0017,1618,712
Other (expense) income, net(107)283260(107)
Total other income1,9063,2847,4218,605
Income (loss) before income taxes1,660(10,437)(17,320)(35,009)
Income tax benefit (expense)15(200)74(139)
Net income (loss)$1,675$(10,637)$(17,246)$(35,148)
Net income (loss) per share (Note 3):
Basic$0.03$(0.20)$(0.32)$(0.67)
Diluted$0.03$(0.20)$(0.32)$(0.67)
Weighted-average shares used to compute net income (loss) per share:
Basic52,507,58252,903,33854,016,44652,266,106
Diluted53,736,79052,903,33854,016,44652,266,106
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.